Clinical trials: Liver Disease; Alcohol-Related
Alcohol Use Disorder, Alcohol; Liver
CM for Patients With ALD After Liver Transplant
Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S.
- Conditions
- Alcohol Use Disorder, Alcohol; Liver, Post Liver Transplant, Contingency Management
- Trial name
- NCT06304467
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Arpan A. Patel, MD
HIV/AIDS, Alcoholic Hepatitis
Immunology of HIV and Alcoholic Hepatitis
This is prospective, longitudinal cohort study involving HIV-positive, antiretroviral (ART)-treated, heavy alcohol drinking participants who have and do not have alcoholic hepatitis.
- Trial name
- NCT03951662
- Testing
- Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
- Where
- United States
- Sponsor
- Indiana University
Alcohol-related Liver Disease, Alcohol Use Disorder
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.
Excessive alcohol use is a leading risk factor for preventable disability and death. Alcohol-related liver disease (ALD) is one of the better-known detrimental consequences of alcohol abuse and is the main cause of…
- Conditions
- Alcohol-related Liver Disease, Alcohol Use Disorder, Metabolic and Alcohol Related/Associated Liver Disease, Metabolic Disfunction Associated Steatotic Liver Disease
- Trial name
- StopALD (NCT06403332)
- Testing
- brief intervention
- Where
- 2 sites in Spain
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Severe Alcoholic Hepatitis
Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis
Severe alcoholic hepatitis, defined by a "Maddrey discriminant function" above 32, is associated with significant short-term mortality.
- Trial name
- CALPRO-HAA (NCT02808663)
- Testing
- fecal calprotectin concentration, blood collection
- Where
- France
- Volunteers
- 6 people
- Sponsor
- CHU de Reims
Cirrhosis Alcoholic, Fatigue Symptom
Inflammatory and Neuroimmune Guided Investigation of Underlying Fatigue in Patients With Cirrhosis
Fatigue is a common and debilitating symptom of cirrhosis, the advanced stage of chronic liver disease. Around two-thirds of people with cirrhosis experience fatigue, which can affect their ability to carry out everyday…
- Trial name
- IGNITE (NCT07899736)
- Volunteers
- 50 people
- Sponsor
- King's College London
Severe Alcoholic Hepatitis
Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome
Alcoholic liver disease has become one of the foremost causes of chronic liver disease across the world, and a cause of considerable morbidity and mortality.
- Trial name
- NCT03827772
- Testing
- Fecal Microbiota Transplantation, Standard of care treatment
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Severe Alcoholic Hepatitis, Chronic Liver Disease and Cirrhosis
Invasive Fungal Infections in Severe Alcohol-associated Hepatitis
Chronic alcohol consumption is associated with intestinal bacterial dysbiosis, yet little is known about the role of intestinal fungi, or mycobiota in liver disease.
- Trial name
- NCT04103840
- Testing
- Testing stool mycobiota
- Where
- India
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Alcoholic Hepatitis
Use of F-652 in Patients With Alcoholic Hepatitis
Alcoholic hepatitis is a syndrome of progressive inflammatory liver injury associated with long-term heavy intake of ethanol. The pathogenesis is not completely understood.
- Trial name
- TREAT 008 (NCT02655510)
- Testing
- F-652
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Liver Diseases, Alcoholic, Alcohol Use Disorder
Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial
To evaluate the efficacy of systematically offering newly diagnosed ALD patients to AUD treatment, in the hepatology clinic, on alcohol abstinence after 6 months.
- Conditions
- Liver Diseases, Alcoholic, Alcohol Use Disorder, Treatment Adherence, Alcoholism
- Trial name
- NCT06493773
- Testing
- Offer of specialized alcohol use disorder treatment in the hepatology clinic
- Where
- Denmark
- Volunteers
- 221 people
- Sponsor
- Zealand University Hospital
Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
Background: Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and it has grown more prevalent in the United States.
- Conditions
- Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Alcoholic, Hepatitis, Chronic
- Trial name
- NCT00913757
- Where
- 2 sites in United States
- Volunteers
- 1,871 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular, Hepatitis, Viral, Human
Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer…
- Trial name
- Lipiocis (NCT00116454)
- Testing
- 131 I-lipiodol
- Where
- France
- Volunteers
- 73 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Liver Diseases, Alcoholic, Alcohol-Related Disorders
Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
The purpose of this study is to develop a clinical understanding of early liver transplantation (ELT) for patients with severe alcoholic hepatitis (SAH) and identify the public's opinion regarding this practice.
- Conditions
- Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection
- Trial name
- NCT04234139
- Testing
- liver transplant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Johns Hopkins University
Fatty Liver, Fatty Liver, Alcoholic
Fatty Liver Disease Collaborative Research in China
A multi-center, prospective cohort study on the natural history of fatty liver disease in China
- Conditions
- Fatty Liver, Fatty Liver, Alcoholic, Non-alcoholic Fatty Liver Disease
- Trial name
- FLDCR (NCT02391168)
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Fatty Liver and Alcoholic Liver Disease Study Group, China
Liver Diseases
Identification of Hepatic Fibrosis Using 4D-MRI
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a…
- Trial name
- 4D-MRI Liver (NCT05385237)
- Testing
- 4D-MRI
- Where
- 2 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Alcohol-related Liver Disease
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease.
- Trial name
- NCT06409130
- Testing
- NNC0194-0499, Semaglutide, Cagrilintide + semaglutide
- Where
- 102 sites in United States, Australia and 12 more
- Volunteers
- 270 people
- Sponsor
- Novo Nordisk A/S
Alcoholic Hepatitis
Fecal Microbiota Therapy in Steroid Ineligible Alcoholic Hepatitis
Alcoholic hepatitis, the most florid form of alcoholic liver disease, has a very high short-term mortality of up to 50% and no specific therapies are available other than steroids.
- Trial name
- NCT05285592
- Testing
- Fecal Transplantation, Standard Medical Treatment
- Where
- India
- Volunteers
- 84 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Alcoholic Liver Disease
FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease
Apart from Fibrotest, non-invasive markers have been validated only for chronic hepatitis C. However as for chronic C hepatitis, non invasive tests (Fibrotest and transient elastometry) are already used in current practice.
- Trial name
- FIBROMAF (NCT00708617)
- Where
- 3 sites in France
- Volunteers
- 227 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Cirrhosis, Alcoholic
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis.
- Trial name
- NCT06057870
- Testing
- Application on Apple watch
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Non-Alcoholic Fatty Liver Disease, Liver Disease; Alcohol-Related
FibroScan-Reproducibility and Repeatability Study
Chronic liver disease (CLD) is a serious health issue worldwide, often progressing without symptoms until advanced stages with risks of complications like liver cancer and cirrhosis.
- Trial name
- FibroScan-RR (NCT06877026)
- Testing
- FibroScan, Liver Enzymes
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- Echosens